Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28088573 | 0.81 | CA1 (0.39) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL5162463 | 0.79 | TRPV4 (0.44) | TRPV4MEN1KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL27152694 | 0.79 | SLC22A12 (0.39) | TRPV4HCAR1MEN1KMT2AHSD11B1 | |
| SCHEMBL30681743 | 0.79 | SLC22A12 (0.39) | TRPV4HCAR1MEN1KMT2AHSD11B1 | |
| SCHEMBL6254835 | 0.79 | HSD11B1 (0.40) | TRPV4MEN1KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL4665197 | 0.77 | ALDH1A1 (0.41) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL23726465 | 0.75 | HCAR1 (0.40) | CA2CA1CA5ACA9HCAR1 | |
| SCHEMBL352430 | 0.75 | CA1 (0.43) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL2163749 | 0.75 | CA1 (0.43) | CA2CA1CA4CA6PLCG1 | |
| SCHEMBL11741823 | 0.74 | TRPV4 (0.42) | CA2CA1CA5ACA9TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20090312414-A1 | Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists | THE PROCTER & GAMBLE COMPANY (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009140078-A1 | TREATMENT OF LOWER URINARY TRACT DYSFUNCTION WITH CB2-RECEPTOR-SELECTIVE AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312414-A1 | Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists | CNR2, CNR1, GPR52 | CA2 1915/4885CA1 3301/4885CA4 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.